Global Radiopharmaceuticals Market Overview:
Global Radiopharmaceuticals Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Radiopharmaceuticals Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Radiopharmaceuticals involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Radiopharmaceuticals Market:
The Radiopharmaceuticals Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Radiopharmaceuticals Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Radiopharmaceuticals Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Radiopharmaceuticals market has been segmented into:
SPECT Radioisotopes
PET Radioisotopes
Beta Emitters
Alpha Emitters
Other Product Types
By Application, Radiopharmaceuticals market has been segmented into:
Oncology
Cardiology
Endocrine Tumor
Neurology
Other Applications
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Radiopharmaceuticals market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Radiopharmaceuticals market.
Top Key Players Covered in Radiopharmaceuticals market are:
Actinium Pharmaceuticals Inc.
Advanced Accelerator Applications
Alliance Medical Ltd.
Bayer HealthCare Pharmaceuticals
Bracco Diagnostics Inc.
Cardinal Health Inc.
Curium US LLC
GE Healthcare
IBA Radiopharma Solutions
Jubilant DraxImage Inc.
Lantheus Medical Imaging Inc.
Medi-Radiopharma Ltd.
Nordion Inc.
Radiopharm Theranostics Ltd.
Siemens Healthcare GmbH
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: Radiopharmaceuticals Market Type
4.1 Radiopharmaceuticals Market Snapshot and Growth Engine
4.2 Radiopharmaceuticals Market Overview
4.3 SPECT Radioisotopes
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 SPECT Radioisotopes: Geographic Segmentation Analysis
4.4 PET Radioisotopes
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 PET Radioisotopes: Geographic Segmentation Analysis
4.5 Beta Emitters
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Beta Emitters: Geographic Segmentation Analysis
4.6 Alpha Emitters
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Alpha Emitters: Geographic Segmentation Analysis
4.7 Other Product Types
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Other Product Types: Geographic Segmentation Analysis
Chapter 5: Radiopharmaceuticals Market Application
5.1 Radiopharmaceuticals Market Snapshot and Growth Engine
5.2 Radiopharmaceuticals Market Overview
5.3 Oncology
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Oncology: Geographic Segmentation Analysis
5.4 Cardiology
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Cardiology: Geographic Segmentation Analysis
5.5 Endocrine Tumor
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Endocrine Tumor: Geographic Segmentation Analysis
5.6 Neurology
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Neurology: Geographic Segmentation Analysis
5.7 Other Applications
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Other Applications: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Radiopharmaceuticals Market Share by Manufacturer (2025)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ACTINIUM PHARMACEUTICALS
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 INC.; ADVANCED ACCELERATOR APPLICATIONS; ALLIANCE MEDICAL LTD.; BAYER HEALTHCARE PHARMACEUTICALS; BRACCO DIAGNOSTICS
6.4 INC.; CARDINAL HEALTH
6.5 INC.; CURIUM US LLC; GE HEALTHCARE; IBA RADIOPHARMA SOLUTIONS; JUBILANT DRAXIMAGE INC.; LANTHEUS MEDICAL IMAGING INC.; MEDI-RADIOPHARMA LTD.; NORDION INC.; RADIOPHARM THERANOSTICS LTD.; SIEMENS HEALTHCARE GMBH
Chapter 7: Global Radiopharmaceuticals Market By Region
7.1 Overview
7.2. North America Radiopharmaceuticals Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 SPECT Radioisotopes
7.2.2.2 PET Radioisotopes
7.2.2.3 Beta Emitters
7.2.2.4 Alpha Emitters
7.2.2.5 Other Product Types
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Oncology
7.2.3.2 Cardiology
7.2.3.3 Endocrine Tumor
7.2.3.4 Neurology
7.2.3.5 Other Applications
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe Radiopharmaceuticals Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 SPECT Radioisotopes
7.3.2.2 PET Radioisotopes
7.3.2.3 Beta Emitters
7.3.2.4 Alpha Emitters
7.3.2.5 Other Product Types
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Oncology
7.3.3.2 Cardiology
7.3.3.3 Endocrine Tumor
7.3.3.4 Neurology
7.3.3.5 Other Applications
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe Radiopharmaceuticals Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 SPECT Radioisotopes
7.4.2.2 PET Radioisotopes
7.4.2.3 Beta Emitters
7.4.2.4 Alpha Emitters
7.4.2.5 Other Product Types
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Oncology
7.4.3.2 Cardiology
7.4.3.3 Endocrine Tumor
7.4.3.4 Neurology
7.4.3.5 Other Applications
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific Radiopharmaceuticals Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 SPECT Radioisotopes
7.5.2.2 PET Radioisotopes
7.5.2.3 Beta Emitters
7.5.2.4 Alpha Emitters
7.5.2.5 Other Product Types
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Oncology
7.5.3.2 Cardiology
7.5.3.3 Endocrine Tumor
7.5.3.4 Neurology
7.5.3.5 Other Applications
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa Radiopharmaceuticals Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 SPECT Radioisotopes
7.6.2.2 PET Radioisotopes
7.6.2.3 Beta Emitters
7.6.2.4 Alpha Emitters
7.6.2.5 Other Product Types
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Oncology
7.6.3.2 Cardiology
7.6.3.3 Endocrine Tumor
7.6.3.4 Neurology
7.6.3.5 Other Applications
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America Radiopharmaceuticals Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 SPECT Radioisotopes
7.7.2.2 PET Radioisotopes
7.7.2.3 Beta Emitters
7.7.2.4 Alpha Emitters
7.7.2.5 Other Product Types
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Oncology
7.7.3.2 Cardiology
7.7.3.3 Endocrine Tumor
7.7.3.4 Neurology
7.7.3.5 Other Applications
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Radiopharmaceuticals Scope:
|
Report Data
|
Radiopharmaceuticals Market
|
|
Radiopharmaceuticals Market Size in 2025
|
USD XX million
|
|
Radiopharmaceuticals CAGR 2025 - 2032
|
XX%
|
|
Radiopharmaceuticals Base Year
|
2024
|
|
Radiopharmaceuticals Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Actinium Pharmaceuticals Inc., Advanced Accelerator Applications, Alliance Medical Ltd., Bayer HealthCare Pharmaceuticals, Bracco Diagnostics Inc., Cardinal Health Inc., Curium US LLC, GE Healthcare, IBA Radiopharma Solutions, Jubilant DraxImage Inc., Lantheus Medical Imaging Inc., Medi-Radiopharma Ltd., Nordion Inc., Radiopharm Theranostics Ltd., Siemens Healthcare GmbH.
|
|
Key Segments
|
By Type
SPECT Radioisotopes
PET Radioisotopes
Beta Emitters
Alpha Emitters
Other Product Types
By Applications
Oncology
Cardiology
Endocrine Tumor
Neurology
Other Applications
|
